Immunophenotype outliers with benign diagnosis and negative for lymphoma on follow-up: demographics and related markers
| Kappa:lambda ratio >3:1 or <1:1 | N | M:F | Age | K:L (LG) | K:L (LCG) | CD10 (LG) | CD10 (LCG) |
| Lymphocyte K:L <1:1 Gate K:L >3:1 | 5 | 2:3 | 38.6 (3–63) | 0.7 (0.4–0.9) 3.1 | 1 (0.3–1) No data | 36 (9-71)† | 43 (16–64) |
| Large cell K:L <1:1 Gate K:L >3:1 | 17 | 7:9 | 25.1 (3–76) | 1.1 (0.4–1.5) 1.6 (1.5–2.3) | 0.9 (0.3–0.9) 3.8 (3.1–5.5) | 11 (0–50) | 36 (5–86) |
| CD10/19 outliers* | N | M:F | Age | K:L (LG) | K:L (LCG) | CD10 (LG) | CD10 (LCG) |
| Lymphocyte gate | 5 | 3:2 | 39.6 (3–68) | 1.8 (1.5–3.1) | 1.4 (1.3–2.6) | 74 (69–90) | 84 (84–94) |
| Large cell gate | 5 | 4:1 | 29.5 (5–68) | 1.6 (1.0–1.7) | 1.4 (1–2.6) | 60 (14–69) | 94 (88–97) |
| CD5/19 outliers* | N | M:F | Age | K:L (LG) | K:L (LCG) | CD5 (LG) | CD5 (LCG) |
| Lymphocyte gate | 5 | 4:1 | 13† (2–42) | 1.5 (1.2–1.8) | 1.1 (0.9–1.2) | 41 (40–57) | 40 (27-65)† |
| Large cell gate | 5 | 3:2 | 31.4 (2–70) | 1.2 (1.1–1.4) | 1.2 (1.1–1.4) | 31 (0–57) | 65 (57–100) |
| CD4:CD8 >10:1/<1:1 | N | M:F | Age | CD4:CD8 | CD7 loss | CD56+CD3+ | CD57+CD3+ |
| CD4:CD8 <1:1 (lowest 10) | 10 | 7:3 | 31 (3–68) | 0.7 (0.3–0.9) | −1.5 (−13 to 29) | 0 (0–7) | 1 (0–25) |
| CD4:CD8 >10:1 (top 10) | 10 | 5:5 | 30.5 (2–74) | 17.1 (14.6–36) | 0 (−4 to 12) | 0 (0–0) | 3 (1–7) |
| CD7 loss outliers* | N | M:F | Age | CD4:CD8 | CD7 loss | CD56+CD3+ | CD57+CD3+ |
| 10 | 4:6 | 36.5 (5–68) | 3.5 (0.7–6.8) | 28 (16–80) | 0.5 (0–4) | 4 (1–16) |
*Outlier defined as greater than 1.5 times the IQR above the third quartile. One overlapping case between kappa:lambda and CD10, one between kappa:lambda and CD5, one between kappa:lambda LG and LCG.
†Significant difference compared with all non-outliers, p<0.01 (Mann-Whitney-Wilcoxon test).
K:L, kappa:lambda; LCG, large cell gate; LG, lymphocyte gate; M:F, male-to-female ratio; N, sample size.